Cell Therapy Supply Chain Logistics Associate

Cell Therapy Supply Chain Logistics AssociateNexcella, Inc.Sao Paulo / HybridOur 3 Core Values- Intelligence- Integrity- InitiativeWhat You'll DoOverseeing the patient journey from screening through treatment across CAR-T therapies You will work cross-functionally with internal and external stakeholders to ensure therapies reach patients as quickly and efficiently as possible.Key ResponsibilitiesYou will play a key role in supporting our Global Patient Supply Operations:- Work cross functionally between clinical operations, manufacturing, and quality to effectively manage patient products from leukapheresis collection through drug- product infusion- Develop and improve SOPs, work instructions, and training materials which are used to ensure seamless end to end patient journey- Manage logistics providers which are responsible for transportation of patient- material (starting material, intermediates, and final product)- Ensure chain of custody (COC) and chain of Identity (COI) measures are maintained throughout all patient journey activities- Support CMO activities which includes logistics support for all patient related- material including CMO storage capacity management- Support/manage clinical sites as primary point of contact (POC) for scheduling and- general inquiries regarding patient journey activitiesQualifications- Bachelor's or Master's degree in relevant discipline (or equivalent experience)- 1-5 years of work experience or the equivalent combination of education and- experience- Previous industry experience in a biotech or pharma companyAbout Nexcella, Inc.Nexcella, Inc. is a subsidiary of Immix Biopharma, Inc. (ImmixBio) (Nasdaq:IMMX), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases.
Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 with a "digital filter" that filters out non-specific activation.
NXC-201 is being evaluated in the U.S. multi-center study for relapsed/refractory AL Amyloidosis NEXICART-2 (NCT06097832), with a registrational design.
Interim results were presented at ASCO 2025 in an oral presentation by Heather Landau, M.D. of Memorial Sloan Kettering Cancer Center.
NXC-201 has been awarded Regenerative Medicine Advanced Therapy (RMAT) by the US FDA and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA.
Learn more at and .